PNAS:研究发现E蛋白家族成员E2-2通过影响AETFC复合体负性调控白血病发生

2019-01-05 佚名 上海营养与健康研究院

近日,国际学术期刊《美国国家科学院院刊》(PNAS)在线发表了中国科学院上海营养与健康研究院王兰研究组与上海交通大学附属瑞金医院孙晓建研究组和美国洛克菲勒大学Robert G. Roeder组的合作研究论文“Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and ne

近日,国际学术期刊《美国国家科学院院刊》(PNAS)在线发表了中国科学院上海营养与健康研究院王兰研究组与上海交通大学附属瑞金医院孙晓建研究组和美国洛克菲勒大学Robert G. Roeder组的合作研究论文“Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis”,该研究发现E蛋白家族成员E2-2能够通过影响AETFC(AML1-ETO-containing transcription factor complex)复合体功能从而负性调控AML1-ETO融合蛋白诱导的t(8;21)急性髓系白血病的发生。

致病融合蛋白AML1-ETO在t(8:21)白血病发生的过程中发挥着至关重要的作用,AML1-ETO在白血病细胞中是作为一个稳定的蛋白复合物而存在和发挥功能的,研究人员命名这个复合体为AETFC。AETFC的成员蛋白HEB和E2A属于E蛋白家族,对于AML1-ETO介导的t(8;21)白血病发生是非常重要的。有意思的是,研究人员发现E蛋白的第三个成员E2-2在t(8;21)白血病细胞中是不表达的,提示E2-2可能是t(8;21)白血病发生的负调控因子。因此研究E2-2在白血病发生中的作用及其机理,能够进一步加深对白血病发病机制的理解,对白血病的临床诊断和治疗具有重要的指导意义。

研究发现,过表达E2-2可以特异性地抑制携带AML1-ETO融合基因的Kasumi-1细胞生长,并且该作用是依赖于E2-2的bHLH(basic helix-loop-helix)结构域的。对Kasumi-1细胞进行了RNA-seq和ChIP-seq的分析,发现E2-2能将AETFC转移到一些新的靶基因上,激活与细胞分化相关的基因例如THPO,诱导白血病细胞向树突状细胞分化。在白血病患者标本中,E2-2的表达在M2b亚型中相对较低,并且E2-2的靶基因THPO的表达水平与患者的复发率存在相关性;在小鼠模型中,抑制E2-2的表达能够加快AML1-ETO介导的白血病发生。这些结果表明E2-2可能形成一个新的AETFC亚型,通过调控AETFC异质性从而扮演了t(8:21)白血病的负调控因子的角色。


图:E蛋白家族成员HEB, E2A和E2-2在白血病发生过程中所扮演的不同角色式。

该项研究得到科技部国家重点研发计划、国家自然科学基金委、中科院科研基金、医学基因组学国家重点实验室等的资助,同时也得到上海营养与健康院公共技术平台以及动物平台的支持。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1856260, encodeId=50321856260bb, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Jan 28 00:01:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753452, encodeId=90201e5345219, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 27 03:01:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717437, encodeId=f1b41e1743705, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Jul 14 03:01:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937738, encodeId=d4a5193e738cf, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Sep 05 22:01:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
    2019-01-28 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1856260, encodeId=50321856260bb, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Jan 28 00:01:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753452, encodeId=90201e5345219, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 27 03:01:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717437, encodeId=f1b41e1743705, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Jul 14 03:01:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937738, encodeId=d4a5193e738cf, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Sep 05 22:01:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1856260, encodeId=50321856260bb, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Jan 28 00:01:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753452, encodeId=90201e5345219, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 27 03:01:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717437, encodeId=f1b41e1743705, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Jul 14 03:01:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937738, encodeId=d4a5193e738cf, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Sep 05 22:01:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1856260, encodeId=50321856260bb, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Jan 28 00:01:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753452, encodeId=90201e5345219, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 27 03:01:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717437, encodeId=f1b41e1743705, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Jul 14 03:01:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937738, encodeId=d4a5193e738cf, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Sep 05 22:01:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
    2019-09-05 bioon1

相关资讯

迅速落地!医院开始接收患白血病儿童,英国医保正式覆盖CAR-T疗法

近日,英国国家医疗保健体系(NHS)宣布,第一批受益于诺华公司CAR-T疗法的儿童将于本周在伦敦大奥蒙德街医院开始接受治疗。

Sci Transl med:白血病患者福音!新发现有望提高“造血干细胞移植”成功率

白血病是危害人类健康的重大疾病之一,治愈这类疾病最有效的手段是造血干细胞移植。本周,顶级期刊《科学》子刊上发表了一项重要成果,有望显着提高造血干细胞移植的成功率和安全性。

18个月患儿对症治疗后仍间断发热 你的考虑是?

1岁半女患儿,入院前一周在家无明显诱因下出现发热,热型不详,无昏厥、抽搐,无气促、发绀,无呕吐、腹泻、无黑便及血尿,对症处理后仍然间断发热。未明确诊断,应做哪些相关检查?如何确诊?

Gene Dev:儿童MLL型白血病或迎重大突破,新靶点被发现

在儿童高发的肿瘤类型中,儿童白血病的发病人数一直占所有儿童常见肿瘤的前列,由于这种恶性肿瘤与遗传因素具有很强关联性,因此其治疗方案一般需要采取较为特殊的方案,但其最终的治疗成功率仍然不能满足现状。

CAR-T治疗复发难治急性B淋巴细胞白血病缓解率高

“对110例高危复发/难治B-ALL患者进行CD19 CAR-T细胞治疗后,92.7%的患者获得了完全缓解或部分缓解,87.3%的患者获得了MRD阴性的完全缓解。”北京陆道培医院普通血液及免疫治疗科主任张弦在近日举行的2018年第60届美国血液学会年会上表示。

CLIN CANCER RES:三代CART治疗淋巴瘤和白血病

嵌合抗原受体(CAR)T细胞疗法对CD19 + B细胞恶性肿瘤患者有效。CAR受体中结合CD28或4-1BB共刺激结构域是第二代CAR。CLIN CANCER RES近期发表了一篇文章,评估针对CD19的第三代CAR T细胞的安全性和有效性。